This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability
- Thyroid Carcinoma
- Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer
- A Highly Sensitive Thyroglobulin Assay Has Superior Diagnostic Sensitivity for Recurrence of Differentiated Thyroid Cancer in Patients Undergoing TSH Suppression
- Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning
- Is Empiric 131I Therapy Justified for Patients with Positive Thyroglobulin and Negative 131I Whole-Body Scanning Results?
- Empirically Treating High Serum Thyroglobulin Levels
- The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma
- Predictive Value for Disease Progression of Serum Thyroglobulin Levels Measured in the Postoperative Period and After 131I Ablation Therapy in Patients with Differentiated Thyroid Cancer
- Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy
- Effect of a Diagnostic Dose of 185 MBq 131I on Postsurgical Thyroid Remnants
- Thyroglobulin IRMA Pasteur Immunoassay: Sensitivity of the Assay and Interference from Thyroglobulin Autoantibodies The authors of the above-mentioned article and editorial reply: